Why "Research Use Only" Does Not Protect a Peptide Business

Quick answer

A "Research Use Only" label does not stop FDA from treating a peptide as a drug. FDA judges a product's intended use from objective evidence, including labeling claims, advertising and the circumstances of its distribution (21 C.F.R. § 201.128), and its 2024 to 2026 warning letters to peptide sellers set aside research-use and not-for-human-use statements. Those letters charge the sellers with selling unapproved new drugs under 21 U.S.C. § 355(a) and § 331(d). The compliant route runs through a licensed prescriber, not a disclaimer, and a prescriber does not make an unapproved or non-compoundable peptide lawful.

This article is for prescriber-led clinics, telehealth operators, med spas and their marketers. It is part of our peptide advertising compliance guide.

What does "Research Use Only" mean under FDA rules?

Much less than sellers assume. FDA's "Research Use Only" labeling rule for diagnostics, 21 C.F.R. § 809.10(c), sits in the rules for in vitro diagnostic products. It lets an IVD product in the laboratory research phase ship without the usual labeling if all labeling carries the statement "For Research Use Only. Not for use in diagnostic procedures," prominently placed. It does not apply to peptides sold as chemicals, and no FDA regulation creates an "RUO" status for research peptides.

The regulation also sets no type size. The only standard it states is "prominently placed." Claims that a 12-point bold warning, or any particular font, makes a research label compliant have no source in FDA or FTC rules.

FDA's 2013 guidance on IVDs labeled RUO, which is nonbinding and covers diagnostics only, shows how the agency thinks about the label. It says intended use "may be determined by looking at the totality of circumstances surrounding the distribution of the article," and that a product can be "actually intended for clinical use despite the RUO or IUO labeling" (FDA guidance, November 25, 2013). That guidance is about diagnostics, so read it as an analogy. The direct evidence for peptides is the warning letters below.

How does FDA decide what a product is intended for?

By looking at what the seller does, not only at what the label says. Under 21 C.F.R. § 201.128, intended use refers to "the objective intent of the persons legally responsible for the labeling of an article." The regulation says that intent "may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article," and gives "labeling claims, advertising matter, or oral or written statements" as examples.

That is why a disclaimer cannot carry the weight sellers put on it. A label is one expression. Product pages, blog posts, social accounts, the products sold alongside, and the way the business presents itself are all evidence of intent, and FDA reads them together.

What do FDA's warning letters to peptide sellers say?

The four 2026 letters reviewed here open the same way. FDA quotes the seller's research disclaimer and then sets it aside. From the letter to Gram Peptides dated March 31, 2026: "Despite statements on your product labeling marketing your products for 'Research Use Only,' and 'not intended for human consumption, medical use, or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use" (FDA warning letter).

Company	Letter date	What the letter cited as evidence of human use
Summit Research Peptides	Dec 10, 2024	Products labeled "RESEARCH USE ONLY" and "INTENDED AS A RESEARCH CHEMICAL ONLY." FDA also reviewed the firm's Facebook page.
Xcel Research LLC	Dec 10, 2024	Claims phrased as effects on "research test subjects."
Prime Vitality, Inc. dba Prime Peptides	Dec 10, 2024	Instagram, Facebook and YouTube posts, including a "TESTIMONIALS" post about retatrutide weight loss.
USApeptide.com	Feb 26, 2025	Bacteriostatic water and insulin syringes sold alongside. This letter also cites misbranding for lack of adequate directions for use.
Gram Peptides	Mar 31, 2026	Website copy on weight, glucose and appetite. Bacteriostatic water sold alongside the peptides.
Prime Sciences	Mar 31, 2026	Coded product names that FDA decoded, including "GLP1-S," which the letter identifies as semaglutide. Copy that read "Ozempic – Weight Loss Supplement." Labels that said "laboratory research purposes only."
Wholesale Peptide	Jun 17, 2026	Disease claims such as "Prostamax for Enlarged Prostate," on products labeled "RESEARCH USE ONLY."
Royal Peptides LLC	Aug 24, 2026	Blog comparison posts treated as labeling. A "peptide guide" and "peptide calculator" marketed alongside bacteriostatic water.
TXP Innovations LLC dba Tex Peptides	Aug 24, 2026	Bacteriostatic water marketed as a solvent for the firm's products.

What the pattern shows

Read together, the letters show FDA drawing intended use from every part of the business:

Website and blog content, including blog comparison posts treated as labeling (Royal Peptides).
Social media and testimonials on Instagram, Facebook and YouTube (Prime Peptides).
Coded names and research framing, neither of which helped (Prime Sciences, Xcel).
What is offered together. The Royal Peptides letter says the firm marketed bacteriostatic water "alongside a 'peptide guide' and 'peptide calculator,' resources that collectively provide the means to prepare an injectable drug for human administration."

None of this is a list of items to delete. FDA reads the business as a whole. A business whose customers buy peptides to put in their own bodies leaves that evidence in its copy, its community, its catalog and its support, and a disclaimer does not erase it.

Which laws do the letters cite, and what are the penalties?

The usual charge is selling an unapproved new drug. The 2026 letters to Gram Peptides, Prime Sciences, Wholesale Peptide and Royal Peptides all cite § 201.128 for intended use, find the products to be unapproved new drugs under section 505(a) of the FD&C Act, and find that shipping them violates section 301(d).

Statute	What it does
21 U.S.C. § 355 (FD&C Act § 505)	A "new drug" may not be shipped in interstate commerce without an FDA-approved application.
21 U.S.C. § 331 (§ 301)	Lists prohibited acts, including shipping a drug in violation of § 355 (paragraph d) and shipping an adulterated or misbranded drug (paragraph a).
21 U.S.C. § 333 (§ 303)	Penalties. A § 331 violation is a misdemeanor punishable by up to one year in prison. A repeat violation, or one committed "with the intent to defraud or mislead," is a felony punishable by up to three years.
21 U.S.C. § 352 (§ 502)	Defines misbranding, including inadequate directions for use (paragraph f).

None of those four 2026 letters cites misbranding. The February 26, 2025 letter to USApeptide.com cites both the unapproved new drug charge and misbranding under section 502(f)(1), for lack of adequate directions for use (FDA warning letter).

Do platforms, processors or the FTC accept the disclaimer?

No. The same reasoning appears outside FDA, and each gatekeeper can end a business faster than an enforcement action.

The FTC. FTC staff guidance on health products says a disclosure "can't directly contradict a claim" (Health Products Compliance Guidance, p.9). A "not for human consumption" line next to copy about human results is that kind of contradiction.
LegitScript. In its October 30, 2025 analysis of peptide risk, LegitScript wrote that disclaimers such as "not for human consumption" are "often a red flag rather than a legal protection" (LegitScript).
Card networks. Visa's rules require acquirers to keep cards from being used to buy "products that claim or imply a similar efficacy as prescription drugs, controlled substances, or recreational/street drugs, irrespective of claims of legality" (Visa Core Rules, April 18, 2026, § 1.9.2.1).
Stripe. As of October 2026, Stripe's prohibited list includes "Incorrectly labeled research chemicals" (Stripe). Its FAQ says it will "assume that peptides sold where no purpose is specified are sold for human consumption," and that prescription peptides require preapproval (Stripe FAQ).
Google Ads. As of October 2026, Google treats offering prescription drugs without a prescription as an egregious violation under its unauthorized pharmacies policy: accounts are suspended on detection, without prior warning, and may not advertise again (Google Ads policy).

For the platform detail, see Google, Meta and TikTok ad rules for peptide and GLP-1 clinics. For processors and the MATCH list, see payment processing for peptide and telehealth businesses.

Is BPC-157 a special case?

It is often described as being on FDA's "Category 2" list. That is out of date. As of October 4, 2026:

FDA's Category 2 page lists BPC-157 under bulk drug substances "nominated but withdrawn," with the note that these substances, previously in Category 2, "were withdrawn by the nominators" (FDA). The page keeps FDA's safety text, which says compounded drugs containing BPC-157 "may pose risk for immunogenicity for certain routes of administration."
BPC-157 is not on the 503A bulks list. FDA's briefing document for its July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting proposed "not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List" (FDA briefing document). No final FDA decision is posted.

The 503A bulks list concerns compounding, and nothing in this review makes "research" peptide sales lawful. FDA sent the warning letters above to research-peptide sellers in the same period.

What is the compliant alternative?

Put a licensed prescriber between the patient and the product. That is the model the certification routes below are written for.

Care before a prescription. LegitScript's certification standards require that "a prescription or prescription drug must not be prescribed or dispensed prior to the provision of care by a licensed medical professional," and that a business not facilitate prescribing or dispensing of unapproved medications (LegitScript standards).
Certified channels. As of October 2026, Google allows US telemedicine ads only from LegitScript-certified providers, and online pharmacy ads only from pharmacies accredited by LegitScript or NABP, plus Google's own certification (Google Ads). Meta requires online pharmacies and telehealth providers advertising prescription drugs to hold active LegitScript certification and Meta authorization (Meta).
Truthful claims. A prescriber-led model still has claim limits, especially for compounded drugs. See what a peptide or GLP-1 clinic can and cannot say in ads.

The checkout has to match the model. LUKE's prescription-gated checkout means a product the clinic flags as requiring a prescription cannot be purchased without an active, verified prescription, enforced at checkout and in the database. The clinic decides which products are flagged, and its prescribers decide who gets a prescription.

Legal disclaimer: This article is for informational purposes only and is not legal, regulatory or compliance advice. FDA enforcement, platform policies and processor terms change. Consult qualified legal counsel before selling, prescribing or advertising any peptide. Information reflects primary sources checked on October 4, 2026.

Prescriber-Led Peptide Programs, Built In

LUKE gives clinics prescription-gated checkout: a product the clinic flags as requiring a prescription cannot be purchased without an active, verified prescription, enforced at checkout and in the database. Advertising and marketing services are provided by Ernesto Cullari Media LLC, LUKE's agency partner, under a separate agreement. They are not part of a LUKE software subscription. Read about advertising services.

Request a Demo Read the peptide advertising compliance guide →

Frequently asked questions

Does a "Research Use Only" label make it legal to sell peptides online?

No. FDA judges intended use from objective evidence such as labeling claims, advertising and the circumstances of distribution, under 21 C.F.R. § 201.128. In its 2026 warning letters to Gram Peptides, Prime Sciences, Wholesale Peptide and Royal Peptides, FDA set aside "Research Use Only" and "not for human consumption" statements and found the products to be unapproved new drugs under 21 U.S.C. § 355(a), shipped in violation of § 331(d).

Can FDA use a peptide seller's blog posts and social media as evidence?

Yes. FDA's August 24, 2026 warning letter to Royal Peptides LLC treated blog comparison posts as labeling. Its December 10, 2024 warning letter to Prime Vitality, Inc. dba Prime Peptides cited Instagram, Facebook and YouTube posts, including a testimonials post about retatrutide weight loss.

Do coded product names like "GLP1-S" avoid FDA scrutiny?

No. In its March 31, 2026 warning letter to Prime Sciences, FDA decoded the product name "GLP1-S" as semaglutide.

Is there a required font size for a "Research Use Only" warning?

No. FDA's RUO labeling rule for diagnostics, 21 C.F.R. § 809.10(c), applies to in vitro diagnostic products and requires the statement to be "prominently placed" without setting a type size. No FDA or FTC rule sets a font size for an RUO warning on peptides, and FDA's warning letters found that research-use statements did not change the result.

Is BPC-157 on FDA's Category 2 list?

No, as of October 4, 2026. FDA's Category 2 page lists BPC-157 among substances that were nominated and then withdrawn by their nominators. BPC-157 is not on the 503A bulks list, FDA's July 2026 briefing document proposed not adding it, and no final FDA decision is posted.

What should a peptide business do instead of research-use marketing?

Use a prescriber-led model. A licensed clinician provides care before any prescription, products that require a prescription are dispensed only against one, and advertising runs through certified channels, such as LegitScript certification, which Google requires for telemedicine ads and Meta requires for prescription-drug ads. Claims still need substantiation, and compounded drugs carry FDA's specific claim limits.